1st Edition
Multiple Myeloma and Related Disorders
History of multiple myeloma
Epidemiology and etiology of plasma cell neoplasms
Part 2.
The immune system in myeloma
Molecular biology and cytogenetics
Biology of the malignant plasma cell
Pathophysiology of myeloma bone disease
Part 3.
Clinical features
Hematologic investigations: Morphologic and phenotypic
Part 4.
Biochemical and immunological investigations
The role of imaging in multiple myeloma
Innovative approaches for diagnosis and monitoring
Differential diagnosis and prognosis
Part 5.
Principles of management
Chemotherapy, steroids and interferon
Radiotherapy
Autologous stem cell transplantation
Allogeneic transplantation and treatment with donor lymphocytes
Supportive care
Biological basis of therapy: New molecular targets
Immunotherapeutic approaches
Part 6.
Management of bone disease
Management of myeloma patients with renal failure
Neurologic aspects of monoclonal gammopathy of undetermined significance, multiple myeloma, and related disorders
Part 7.
Monoclonal gammopathies of undetermined significance: the transition from MGUS to myeloma
Solitary bone and extramedullary plasmacytoma
Plasma cell leukaemia
AL amyloidosis
Heavy-chain diseases
Waldenström’s disease
Biography
Gösta Gahrton MD PhD
Professor, Department of Medicine, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden
Brian G.M. Durie MD
Attending Physician, Department of Hematology and Oncology, Cedars-Sinai Comprehensive Cancer Centre, Los Angeles, CA, USA
Diana M. Samson MD
Senior Lecturer in Haematology, Hammersmith Hospital, London, UK
The publication of this book...has been well timed in that it offers a benchmark reference for the specialist in this field and provides the nonspecialist with a comprehensive overview of the discipline at the beginning of an exciting new period. A copy of this book should be available in every hematology department and on the shelf of every specialist in this field.
New England Journal of Medicine
An impressive list of leaders in the myeloma field has been enrolled in the task to define the state-of-the-art in biology and clinical management of the disease, and the result is a book that is both scientifically sound and user-friendly.
Annals of Oncology 16:337
The authors are to be congratulated on this collection of detailed sections, whose logical sequence leads from basic research to the development of new molecular-targeted drugs.
The Lancet Oncology
